AstraZeneca
AZN
$76.90
Share price
-0.18%
Change (1 day)
3.62%
Change (1 year)
Categories
Market capitalization of AstraZeneca (AZN)
Market cap: $238.42 Billion
As of May 2024 AstraZeneca has a market cap of $238.42 Billion. This makes AstraZeneca the world's 46th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of AstraZeneca from 2001 to 2024
End of year Market Cap
| Year | Market cap | Change |
|---|---|---|
| 2024 | $238.42 B | 14.2% |
| 2023 | $208.77 B | -0.77% |
| 2022 | $210.38 B | 15.94% |
| 2021 | $181.46 B | 38.54% |
| 2020 | $130.98 B | 0.09% |
| 2019 | $130.87 B | 38.6% |
| 2018 | $94.42 B | 8.37% |
| 2017 | $87.12 B | 26.34% |
| 2016 | $68.96 B | -20.23% |
| 2015 | $86.45 B | -3.47% |
| 2014 | $89.56 B | 20.86% |
| 2013 | $74.10 B | 26.41% |
| 2012 | $58.62 B | -2.01% |
| 2011 | $59.82 B | -8.08% |
| 2010 | $65.08 B | -4.44% |
| 2009 | $68.10 B | 14.68% |
| 2008 | $59.39 B | -4.81% |
| 2007 | $62.38 B | -23.95% |
| 2006 | $82.03 B | 5.1% |
| 2005 | $78.05 B | 30.47% |
| 2004 | $59.82 B | -26.96% |
| 2003 | $81.90 B | 35.82% |
| 2002 | $60.30 B | -25.85% |
| 2001 | $81.33 B |
End of Day market cap according to different sources
On May 18th, 2024 the market cap of AstraZeneca was reported to be:
$239.30 Billion
$238.42 Billion
$238.41 Billion
$238.42 Billion
$187.24 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $372.16 B | 56.09% | 🇺🇸 USA |
 Novartis NVS | $209.58 B | -12.10% | 🇨🇭 Switzerland |
 Pfizer PFE | $162.29 B | -31.93% | 🇺🇸 USA |
 Abbott Laboratories ABT | $181.07 B | -24.05% | 🇺🇸 USA |
 Eli Lilly LLY | $731.81 B | 206.93% | 🇺🇸 USA |
 Sanofi SNY | $122.00 B | -48.83% | 🇫🇷 France |
 Biogen BIIB | $33.57 B | -85.92% | 🇺🇸 USA |
 Merck MRK | $332.27 B | 39.36% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $89.25 B | -62.57% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $94.75 B | -60.26% | 🇬🇧 UK |